Research Analysts Set Expectations for Neurogene Q2 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Lifesci Capital reduced their Q2 2026 EPS estimates for Neurogene in a research note issued on Wednesday, May 13th. Lifesci Capital analyst P. Dolezal now forecasts that the company will post earnings per share of ($1.41) for the quarter, down from their prior estimate of ($1.28). Lifesci Capital currently has a “Outperform” rating and a $50.00 price target on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($5.35) per share. Lifesci Capital also issued estimates for Neurogene’s Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.01) EPS and FY2026 earnings at ($4.88) EPS.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09).

A number of other research firms have also weighed in on NGNE. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a report on Tuesday, April 21st. Guggenheim initiated coverage on shares of Neurogene in a report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price for the company. Finally, Canaccord Genuity Group lowered their price target on Neurogene to $180.00 and set a “buy” rating for the company in a research report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $67.00.

Neurogene Stock Performance

NGNE stock opened at $31.27 on Friday. The firm has a fifty day moving average price of $24.07 and a 200 day moving average price of $22.10. Neurogene has a fifty-two week low of $14.65 and a fifty-two week high of $37.27. The firm has a market cap of $494.07 million, a PE ratio of -6.87 and a beta of 1.69.

Institutional Trading of Neurogene

Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets lifted its position in shares of Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Neurogene by 24.7% during the third quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after purchasing an additional 1,000 shares during the last quarter. ADAR1 Capital Management LLC lifted its position in shares of Neurogene by 3.4% during the third quarter. ADAR1 Capital Management LLC now owns 30,633 shares of the company’s stock worth $531,000 after purchasing an additional 1,008 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Neurogene by 12.8% during the first quarter. Bank of New York Mellon Corp now owns 26,043 shares of the company’s stock worth $525,000 after purchasing an additional 2,950 shares during the last quarter. 52.37% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Stuart Cobb sold 6,797 shares of Neurogene stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the completion of the sale, the insider directly owned 30,497 shares in the company, valued at approximately $634,642.57. This trade represents a 18.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Christine Mikail Cvijic sold 9,600 shares of Neurogene stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $31.25, for a total value of $300,000.00. Following the sale, the chief financial officer owned 93,640 shares of the company’s stock, valued at approximately $2,926,250. This trade represents a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 20,442 shares of company stock valued at $525,622. 11.64% of the stock is owned by corporate insiders.

Neurogene Company Profile

Neurogene, Inc is a clinical?stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno?associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9?based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.